TROP-2 was suggested as a biomarker to determine the clinical prognosis and as a potential therapeutic target in colon cancer [88, 89] and an antibody-drug conjugate targeting TROP-2 is currently in phase II clinical trials [90]. Here, TACSTD2 is linked to colonic neoplasm.